The medicinal perspective of 2,4-thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review
dc.contributor.author | Kajal, Kumari | |
dc.contributor.author | Singh, Gurpreet | |
dc.contributor.author | Pradhan, Tathagata | |
dc.contributor.author | Bhurta, Deendyal | |
dc.contributor.author | Monga, Vikramdeep | |
dc.date.accessioned | 2024-01-21T10:38:22Z | |
dc.date.accessioned | 2024-08-13T12:05:18Z | |
dc.date.available | 2024-01-21T10:38:22Z | |
dc.date.available | 2024-08-13T12:05:18Z | |
dc.date.issued | 2022-06-18T00:00:00 | |
dc.description.abstract | 2,4-Thiazolidinedione (2,4-TZD), commonly known as glitazone, is a ubiquitous heterocyclic pharmacophore possessing a plethora of pharmacological activities and offering a vast opportunity for structural modification. The diverse range of biological activities endowed with a novel mode of action, low cost, and easy synthesis has attracted the attention of medicinal chemists. Several researchers have integrated the TZD core with different structural fragments to develop a wide range of lead molecules against various clinical disorders. The most common sites for structural modifications at the 2,4-TZD nucleus are the N-3 and the active methylene at C-5. The review covers the recent development of TZD derivatives such as antimicrobial, anticancer, and antidiabetic agents. Various 2,4-TZD based agents or drugs, which are either under clinical development or in the market, are discussed in the study. Different synthetic methodologies for synthesizing the 2,4-TZD core are also included in the manuscript. The importance of various substitutions at N-3 and C-5 and the mechanisms of action and structure�activity relationships are also discussed. We hope this study will serve as a valuable tool for the scientific community engaged in the structural exploitation of the 2,4-TZD core for developing novel drug m\olecules for life-threatening ailments. � 2022 Deutsche Pharmazeutische Gesellschaft. | en_US |
dc.identifier.doi | 10.1002/ardp.202100517 | |
dc.identifier.issn | 3656233 | |
dc.identifier.uri | https://kr.cup.edu.in/handle/32116/3547 | |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1002/ardp.202100517 | |
dc.language.iso | en_US | en_US |
dc.publisher | John Wiley and Sons Inc | en_US |
dc.subject | anticancer | en_US |
dc.subject | antidiabetic | en_US |
dc.subject | antimicrobial | en_US |
dc.subject | biological activity | en_US |
dc.subject | heterocyclic compounds | en_US |
dc.subject | in silico studies | en_US |
dc.subject | molecular docking | en_US |
dc.subject | SAR | en_US |
dc.subject | thiazolidinedione | en_US |
dc.title | The medicinal perspective of 2,4-thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review | en_US |
dc.title.journal | Archiv der Pharmazie | en_US |
dc.type | Review | en_US |
dc.type.accesstype | Closed Access | en_US |